Literature DB >> 2803299

A novel strategy for producing chimeric bispecific antibodies by gene transfection.

S Songsivilai1, P M Clissold, P J Lachmann.   

Abstract

We have used genetic manipulation to produce chimeric bispecific antibodies. Plasmids containing variable regions of immunoglobulin from a murine hybridoma secreting anti-hepatitis B surface antigen were joined to human constant regions. These chimeric plasmids were introduced into transfectomas, secreting chimeric antibodies to iodo-hydroxy-nitrophenyl, by electroporation. Transfectomas secreting bispecific antibodies were identified. This approach has advantages over the fusion of hybridomas or chemical linking of two antibody molecules and will enable the use of bispecific antibodies in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803299     DOI: 10.1016/0006-291x(89)91713-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy.

Authors:  C Somasundaram; S Matzku; J Schuhmacher; M Zöller
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

3.  Peripheral membrane molecules of leukocytes and NK cytotoxicity.

Authors:  J Kubrycht; P Malíková; N H Huan; A Fiserová; K Bezouska; P Kruzík; K Stajner; V Moravec; M Pospísil
Journal:  Folia Microbiol (Praha)       Date:  1993       Impact factor: 2.099

4.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1990-03-11       Impact factor: 16.971

5.  Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.

Authors:  A Bruynck; G Seemann; K Bosslet
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.